Hyperlipoproteinemia (a) is associated with breast cancer in a Han Chinese population.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
18 Sep 2020
18 Sep 2020
Historique:
entrez:
22
9
2020
pubmed:
23
9
2020
medline:
8
10
2020
Statut:
ppublish
Résumé
To investigate the relationship between serum lipoprotein (a) (LP(a)) levels and breast cancer as well as the clinicopathologic characteristics of breast cancer in a Han Chinese population.This study included 314 breast cancer patients, 51 patients with benign breast tumors, and 185 healthy control subjects. All study subjects were Han Chinese with similar socio-economic backgrounds, who were local residents of Zhoushan, Zhejiang, China or who had lived in Zhoushan for a long period of time. Serum concentrations of LP(a) were determined using a latex-enhanced immunoturbidimetric assay. Clinicopathological characteristics of patients were retrieved from medical records, which included the histopathological type, grade, stage, and molecular subtype of the disease, the expression of estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67, and the level of reproductive hormones. Correlations between 2 groups were evaluated using the Spearman correlation analysis. Associations among ≥3 groups were interpreted using the Kruskal-Wallis H test or the logistic regression test.Elevated serum LP(a) levels were detected in breast cancer patients compared with healthy control subjects, but no significant differences in LP(a) were detected between breast cancer and benign tumor or between benign tumor and healthy control. In breast cancer patients, serum LP(a) levels were inversely associated with HER2 expression, but they were not significantly correlated with any other clinicopathologic characteristics of breast cancer evaluated in this study.Elevated serum LP(a) levels were associated with breast cancer in a Han Chinese population.
Identifiants
pubmed: 32957322
doi: 10.1097/MD.0000000000022037
pii: 00005792-202009180-00019
pmc: PMC7505328
doi:
Substances chimiques
Lipoprotein(a)
0
Receptors, Estrogen
0
Receptors, Progesterone
0
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e22037Références
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394424.
DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin 2019;69:43851.
Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol 2014;15:e27989.
Sun YS, Zhao Z, Yang ZN, et al. Risk factors and preventions of breast cancer. Int J Biol Sci 2017;13:138797.
Horn J, Vatten LJ. Reproductive and hormonal risk factors of breast cancer: a historical perspective. Int J Womens Health 2017;9:26572.
Madigan MP, Ziegler RG, Benichou J, et al. Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst 1995;87:16815.
Pfeffer CM, Ho BN, Singh ATK. The evolution, functions and applications of the breast cancer genes BRCA1 and BRCA2. Cancer Genomics Proteomics 2017;14:2938.
Gruver AM, Portier BP, Tubbs RR. Molecular pathology of breast cancer: the journey from traditional practice toward embracing the complexity of a molecular classification. Arch Pathol Lab Med 2011;135:54457.
Eliyatkin N, Yalcin E, Zengel B, et al. Molecular classification of breast carcinoma: from traditional, old-fashioned way to a new age, and a new way. J Breast Health 2015;11:5966.
Utermann G, Menzel HJ, Kraft HG, et al. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987;80:45865.
Angles-Cano E, de la Pena Diaz A, Loyau S. Inhibition of fibrinolysis by lipoprotein(a). Ann N Y Acad Sci 2001;936:26175.
Tsimikas S, Witztum JL. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Curr Opin Lipidol 2008;19:36977.
Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res 2016;57:195375.
Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31:284453.
Orso E, Schmitz G. Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies. Clin Res Cardiol Suppl 2017;12: (suppl): 317.
Sawabe M, Tanaka N, Mieno MN, et al. Low lipoprotein(a) concentration is associated with cancer and all-cause deaths: a population-based cohort study (the JMS cohort study). PLoS One 2012;7:e31954.
Mieno MN, Sawabe M, Tanaka N, et al. Significant association between hypolipoproteinemia(a) and lifetime risk of cancer: an autopsy study from a community-based Geriatric Hospital. Cancer Epidemiol 2014;38:5505.
Yang HH, Chen XF, Hu W, et al. Lipoprotein(a) level and its association with tumor stage in male patients with primary lung cancer. Clin Chem Lab Med 2009;47:4527.
Li G, Da M, Zhang W, et al. Alteration of serum lipid profile and its prognostic value in head and neck squamous cell carcinoma. J Oral Pathol Med 2016;45:16772.
Garcia-Estevez L, Moreno-Bueno G. Updating the role of obesity and cholesterol in breast cancer. Breast Cancer Res 2019;21:35https://doi.org/10.1186/s13058-019-1124-1
doi: 10.1186/s13058-019-1124-1
Rodrigues Dos Santos C, Fonseca I, Dias S, et al. Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression. BMC Cancer 2014;14:132.
dos Santos CR, Domingues G, Matias I, et al. LDL-cholesterol signaling induces breast cancer proliferation and invasion. Lipids Health Dis 2014;13:16.
Rodriguez-Tomas E, Murcia M, Arenas M, et al. Serum paraoxonase-1-related variables and lipoprotein profile in patients with lung or head and neck cancer: effect of radiotherapy. Antioxidants (Basel) 2019;8:7.
Sahebkar A, Serban MC, Penson P, et al. The Effects of tamoxifen on plasma lipoprotein(a) concentrations: systematic review and meta-analysis. Drugs 2017;77:118797.
Kokoglu E, Karaarslan I, Karaarslan HM, et al. Elevated serum Lp(a) levels in the early and advanced stages of breast cancer. Cancer Biochem Biophys 1994;14:1336.
Galvano F, Malaguarnera M, Vacante M, et al. The physiopathology of lipoprotein (a). Front Biosci (Schol Ed) 2010;2:86675.
Wu Q, Ishikawa T, Sirianni R, et al. 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. Cell Rep 2013;5:63745.
Mitri Z, Constantine T, O’Regan R. The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract 2012;2012:7Article ID 743193. doi:10.1155/2012/743193.
doi: 10.1155/2012/743193